Passage BIO, Inc.
Passage BIO, Inc. (PASG): 2 pipeline candidates · ~8 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.8 months
D/E 2.10 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
N/A
0 buys · 2 sells (180d)
A transparent, data-derived signal for Passage BIO, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$18.0M
Cash
$33.3M
Quarterly Burn
$13.0M
Runway
7.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| pbft02 | Phase 1/Phase 2 |
| unspecified | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
30
Total value held
$9.4M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 623,704 | $4.9M |
| vanguard capital management llc | 227,928 | $1.8M |
| renaissance technologies llc | 133,612 | $1.0M |
| geode capital management, llc | 41,380 | $325K |
| blackrock, inc. | 28,595 | $224K |
| ubs group ag | 27,501 | $216K |
| verdad advisers, lp | 22,128 | $174K |
| diadema partners lp | 19,530 | $153K |
| boothbay fund management, llc | 18,871 | $148K |
| vanguard fiduciary trust co | 17,049 | $134K |
Showing top 10 of 30 institutional holders of Passage BIO, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Passage BIO, Inc.'s pipeline?
Passage BIO, Inc. (PASG) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Passage BIO, Inc.'s lead drug candidate?
Passage BIO, Inc.'s most advanced tracked candidate is pbft02 (Phase 1/Phase 2) for Frontotemporal Dementia.
What is Passage BIO, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Passage BIO, Inc. has approximately 7.8 months of cash runway.
What is Passage BIO, Inc.'s market capitalization?
Passage BIO, Inc.'s market capitalization is approximately $18.0M.
Who is the CEO of Passage BIO, Inc.?
Dr. William Chou M.D. is the chief executive officer of Passage BIO, Inc. (PASG).
Get the full picture on Passage BIO, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.